In ER+/HER2− (from here on referred to as ER+) metastatic breast cancer patients, endocrine therapy is the mainstay treatment, being its efficacy at least equal to chemotherapy with a better toxicity profile [2]. The gene discussed is ESR1; the disease is breast carcinoma.